Fibrinolysis Shutdown in Severe COVID-19: Highly Prevalent but not Independently Predictive of Thrombosis or Poorer Outcomes
- PMID: 35213468
- DOI: 10.1097/XCS.0000000000000007
Fibrinolysis Shutdown in Severe COVID-19: Highly Prevalent but not Independently Predictive of Thrombosis or Poorer Outcomes
Comment on
-
Fibrinolysis Shutdown in COVID-19: Clinical Manifestations, Molecular Mechanisms, and Therapeutic Implications.J Am Coll Surg. 2021 Jun;232(6):995-1003. doi: 10.1016/j.jamcollsurg.2021.02.019. Epub 2021 Mar 22. J Am Coll Surg. 2021. PMID: 33766727 Free PMC article. Review.
References
-
- Meisozo JP, Moore HB, Moore EE. Fibrinolysis shutdown in COVID-19: clinical manifestations, molecular mechanisms, and therapeutic implications. J Am Coll Surg. 2021;232:e995–e1003.
-
- Moore HB, Moore EE, Liras IN, et al. Acute fibrinolysis shutdown after injury occurs frequently and increases mortality: a multicenter evaluation of 2,540 severely injured patients. J Am Coll Surg. 2016;222:e347–e355.
-
- Gomez-Builes JC, Acuna SA, Nascimento B, et al. Harmful or physiologic: diagnosing fibrinolysis shutdown in a trauma cohort with rotational thromboelastometry. Anesth Analg. 2018;127:840–849.
-
- Creel-Bulos C, Sniecinski R. Fibrinolysis shutdown and thrombosis in a COVID-19 ICU. Shock. 2021;55:845–846.
-
- Kruse JM, Magomedov A, Kurreck A, et al. Thromboembolic complications in critically ill COVID-19 patients are associated with impaired fibrinolysis. Crit Care. 2020;24:676.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
